Therapy of T cell lymphomas with pentostatin. Ann N Y Acad Sci 2001 Sep;941:200-5
Date
10/12/2001Pubmed ID
11594574DOI
10.1111/j.1749-6632.2001.tb03724.xScopus ID
2-s2.0-0034809004 (requires institutional sign-in at Scopus site) 17 CitationsAbstract
Pentostatin is a highly lymphocytotoxic agent active in hairy cell leukemia. Several studies also suggest significant activity in T cell lymphomas manifested in the skin. Herein, we will review the studies of pentostatin in these lymphomas and our most recent trial of this agent in heavily pretreated patients with cutaneous and peripheral T cell lymphomas. Overall, the data suggest that pentostatin has significant antitumor activity in these patients, with response rates ranging from 33% to over 70%. Approximately one-third of the responses are complete. The most common side effects include granulocytopenia, nausea, and renal insufficiency. CD4 suppression occurs and may result in an increased risk of herpes zoster infection. Although prolonged remissions have been seen, most responses are short-lived. These observations suggest that further exploration of this agent, in combination with other drugs active in T cell lymphomas, is warranted in this group of diseases.
Author List
Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibiotics, AntineoplasticFemale
Herpes Zoster
Humans
Lymphoma, T-Cell, Cutaneous
Male
Pentostatin
Skin Neoplasms
Treatment Outcome
